Accueil   Diary - News   All news Poxel presents new data on Imeglimin's dual mechanism

Poxel presents new data on Imeglimin’s dual mechanism


POXEL SA, a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, today announced the presentation of novel data on its lead candidate Imeglimin. The results were discussed during two poster presentations at the American Diabetes Association’s 76th Scientific Sessions in New Orleans, Louisiana. Both preclinical studies highlighted Imeglimin’s novel and unique mechanism of action (MoA) and indicated the specific pathways through which Imeglimin improves insulin secretion and action. Imeglimin has completed Phase 2 development in over 850 patients in the US and EU and is currently being studied in a Phase 2b clinical trial program in Japan.


Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to More details are available by clicking here I agree